U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07045935) titled 'Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment' on June 12.
Brief Summary: This randomized, active-controlled, parallel-arm, single-blind trial is to compare the effects of Dopamine agonists (DA) therapy targeting different established treatment strategies on glucose metabolism assessed by an oral glucose tolerance test.
Study Start Date: June 10
Study Type: INTERVENTIONAL
Condition:
Prolactinoma
Intervention:
DRUG: Cabergoline (Dopamine Agonist)
Cabergoline is available in tablet form, with doses of 0.5 mg per tablet. The standard dosing for hyperprolactinemia typically starts at 0.25 mg to...